MEDICAL MANAGEMENT OF RADIOLOGICAL CASUALTIES
暂无分享,去创建一个
[1] A. Schaffner,et al. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. , 1995, The Journal of infectious diseases.
[2] I. Brook,et al. Quinolone therapy of Klebsiella pneumoniae sepsis following irradiation: comparison of pefloxacin, ciprofloxacin, and ofloxacin. , 1990, Radiation research.
[3] H. Deeg,et al. Effect of recombinant canine granulocyte-macrophage colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. , 1994, Blood.
[4] M. Paesmans,et al. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1994, JAMA.
[5] R. Leonard,et al. Emergency department radiation accident protocol. , 1980, Annals of emergency medicine.
[6] I. Brook,et al. Management of postirradiation sepsis. , 2002, Military medicine.
[7] I. Brook,et al. Ofloxacin and penicillin G combination therapy in prevention of bacterial translocation and animal mortality after irradiation , 1991, Antimicrobial Agents and Chemotherapy.
[8] C. Mengoli,et al. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. L. Goodman,et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.
[10] E. Bow,et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] M. Blajchman. Immunomodulation and Blood Transfusion , 2002, American journal of therapeutics.
[12] B. Lichtiger,et al. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study. , 2001, Haematologica.
[13] D. Coyle,et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. , 2003, JAMA.
[14] A. Vorobiev. Acute radiation disease and biological dosimetry in 1993 , 1997, Stem cells.
[15] D. Marquardt. An Algorithm for Least-Squares Estimation of Nonlinear Parameters , 1963 .
[16] S. J. Baum,et al. Symptomatology of acute radiation effects in humans after exposure to doses of 0.5-30 Gy. , 1989, Health physics.
[17] E. Cronkite,et al. Survival of spleen colony-forming units (CFU-S) of irradiated bone marrow cells in mice: evidence for the existence of a radioresistant subfraction. , 1995, Experimental hematology.
[18] C. Lushbaugh,et al. THE IMPORTANCE OF DOSIMETRY TO THE MEDICAL MANAGEMENT OF PERSONS ACCIDENTALLY EXPOSED TO HIGH LEVELS OF RADIATION , 1965 .
[19] M. Levenstein,et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.
[20] H. Horowitz,et al. Fluconazole Prophylaxis of Fungal Infections in Patients with Acute Leukemia: Results of a Randomized Placebo-Controlled, Double-Blind, Multicenter Trial , 1993, Annals of Internal Medicine.
[21] J. Lau,et al. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] H. Deeg,et al. Effects of recombinant canine stem cell factor, a c-kit ligand, and recombinant granulocyte colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. , 1993, Blood.
[23] James Armitage,et al. Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group , 2004, Annals of Internal Medicine.
[24] Baranov Ae,et al. Diagnosis, Clinical Picture and Treatment of the Acute Radiation Disease in Chernobyl Accident Victims , 1989 .
[25] T. Priestman. Clinical studies with ondansetron in the control of radiation-induced emesis. , 1989, European journal of cancer & clinical oncology.
[26] R. Goans,et al. Early dose assessment in criticality accidents. , 2001, Health physics.
[27] I. Brook,et al. Quinolone therapy in the prevention of endogenous and exogenous infection after irradiation. , 1994, The Journal of antimicrobial chemotherapy.
[28] T. Calandra,et al. Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .
[29] D. V. Bekkum. Radiation sensitivity of the hemopoietic stem cell. , 1991 .
[30] E. Bow,et al. Randomized Placebo-Controlled Trial of Fluconazole Prophylaxis for Neutropenic Cancer Patients: Benefit Based on Purpose and Intensity of Cytotoxic Therapy , 1999 .
[31] N. Wald,et al. Radiation accidents with multi-organ failure in the United States , 2005 .
[32] Nicholas Dainiak,et al. The hematologist and radiation casualties. , 2003, Hematology. American Society of Hematology. Education Program.